Immunology

P.A. Volberding, S.W. Lagakos, M.A. Koch, C. Pettinelli, et al., "Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter," The New England Journal of Medicine, 322, 941-9, 5 April 1990. Paul A. Volberding (AIDS Program, San Francisco General Hospital, Calif.): "Establishing a medical intervention for patients with HIV infection who remain asymptomatic has changed our basic concept of this lar

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

P.A. Volberding, S.W. Lagakos, M.A. Koch, C. Pettinelli, et al., "Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter," The New England Journal of Medicine, 322, 941-9, 5 April 1990.

Paul A. Volberding (AIDS Program, San Francisco General Hospital, Calif.): "Establishing a medical intervention for patients with HIV infection who remain asymptomatic has changed our basic concept of this large group of patients. The possibility of offering treatment to patients with asymptomatic infection in a sense defines them as having a disease and adds a powerful support to arguments to encourage the more widespread use of voluntary HIV testing. This, in fact, may be as important as the specific observation in this study that zidovudine can reduce the progression rate of HIV disease in patients who are infected and asymptomatic with fewer than 500 CD4+ cells per cubic ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies